The healthcare industry is in a phase of repositioning. Medical Device Regulation (MDR) creates stricter requirements for quality, traceability and certification. At the same time, consolidation is creating more concentrated competition.
In this dynamic, old certainties have disappeared for medical suppliers: digitization and scale-up are no longer optional, but necessary.
In this, 2026 marks a tipping point. The shift from care to prevention and remote monitoring is drawing new tech players into the market and forcing traditional companies to accelerate digitization. Among other things, this wave of digitization accelerates consolidation in the formation of large European platforms, such as Asker and Duomed.
At the same time, the MDR is further standardizing medical devices, including implants, software, wheelchairs and MRI scanners. These uniform regulations make pan-European businesses more attractive than parties focused on one or a few countries. For the Dutch SME entrepreneur, this means that sitting still is no longer an option.
The challenge: scale vs. agility
Smaller companies face high digitization costs and declining margins. To maintain a level playing field, strategic collaboration is often necessary. The question then becomes: how do you set the right course in this changing force field?
Roadmap: strategic roadmap to 2026
To remain successful as an entrepreneur in the consolidating Healthcare market, you can take the following steps:
Step 1: Internal analysis & ambition setting
Before you look at the market, look at yourself. Ask yourself the questions, among others:
- The business: What is our current position and what factors are influencing our growth?
- Personal ambition: Do you still want to be at the helm in the coming years, or are you looking for an exit?
- Management: Is there a team that can take over the operation if you step back?
Step 2: Strategic mirroring
Put your current direction next to market trends. Make a concrete list of "issues" and determine which decisions need to be made on a financial, functional and personnel level. For example, in the area of digitization, is it realistic to finance the required digitization effort autonomously, or is a partner essential?
Step 3: Partner choice & culture match
If collaboration is the logical step, determine what type of partner suits you:
- Financial partner(private equity): often focused on growth while maintaining a degree of independence.
- Strategic partner (corporate): joining a European platform offers economies of scale, but watch out for the impact on the decision making and loyalty of your staff.
Step 4: Timing & risk management
Timing plays a crucial role. If the company is in the midst of implementing new growth initiatives, it may be wise to postpone an acquisition path until its value is apparent. In addition, it is important to assess the risks of a potential partner, especially if it is a foreign corporate where cultural differences may affect the speed of decision-making or affect bonding with key employees.
Common pitfalls in Healthcare M&A
Entrepreneurs working with a foreign party may underestimate the cultural difference. This can potentially lead to miscommunication, false expectations or slow decision-making. By understanding in advance how the buyer is organized, expectations can be better managed.
Late succession in your own organization also poses a risk, as unexpected departure of key people can cause immediate decline in value. A management team that can function independently in a timely manner prevents vulnerability in the process.
In addition, insufficient preparation for MDR requirements can cause a company to lose its European market access. Getting regulations in order in a timely manner keeps the company attractive to strategic parties. This creates a stronger foundation for a future-proof transaction.
Conclusion: prepare for the movement
The medical device market is showing that economies of scale and technology investment are the new normal. Taking a critical look at your strategy now will turn the challenges of 2026 into a growth opportunity.
